← All trials
NCT07280572
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 17, 2025
- Primary completion
- Dec 1, 2027
- Completion date
- Dec 1, 2027
- First posted
- Dec 12, 2025
- Last posted
- Dec 12, 2025
- Enrollment
- 1250
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Utrecht UniversityLead sponsor
- European Clinical Research Alliance for Infectious Diseases (ECRAID)Collaborator
- Utrecht UniversitySponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.